ArticleClinical epidemiology2017
Misclassification of hypertrophic cardiomyopathy: validation of diagnostic codes.
Article in Clinical epidemiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- An evidence review and gap analysis for obstructive hypertrophic cardiomyopathy.BMC cardiovascular disorders · 2024Pooled it
- Characterizing clinically recognized hypertrophic cardiomyopathy in six European countries using real-world data.ESC heart failure · 2026Observational
- Quantitative imaging analysis in hypertrophic cardiomyopathy: phenotypic differentiation to prognostic stratification.European heart journal. Imaging methods and practice · 2026Review
- Artificial Intelligence for the Detection of Hypertrophic Cardiomyopathy From Standard Electrocardiogram.JACC. Advances · 2026Article
- Long-term outcomes after septal reduction therapy for obstructive hypertrophic cardiomyopathy: a nationwide cohort study.European heart journal open · 2026Article
- Genetic determinants of the phenotype in a Swedish cohort of patients with hypertrophic cardiomyopathy.Scientific reports · 2025Article
- Identification of hypertrophic cardiomyopathy on electrocardiographic images with deep learning.Nature cardiovascular research · 2025Article
- Identification of Hypertrophic Cardiomyopathy on Electrocardiographic Images with Deep Learning.medRxiv : the preprint server for health sciences · 2025Article
- Diagnostic accuracy in the Swedish national patient register: a review including diagnoses in the outpatient register.European journal of epidemiology · 2025Review
- Comprehensive Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy From Other Cardiomyopathies With Left Ventricular Hypertrophy.Circulation. Heart failure · 2025Article
- Associations of sex on economic burden in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from medical and pharmacy claims data.Frontiers in cardiovascular medicine · 2025Article
- Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy.Nature cardiovascular research · 2024Article
- Validity of a Hypertrophic Cardiomyopathy Diagnosis in Adult Patients in the Danish National Patient Register.Clinical epidemiology · 2024Article
- Article
- Impact of a Center of Excellence in Confirming or Excluding a Diagnosis of Hypertrophic Cardiomyopathy.The American journal of cardiology · 2023Article
- Acute Left Ventricular Ballooning: Tools to Differentiate Hypertrophic Cardiomyopathy with Outflow Obstruction from Neurohumoral Takotsubo Syndrome.Reviews in cardiovascular medicine · 2023Review
- Familial risk of dilated and hypertrophic cardiomyopathy: a national family study in Sweden.ESC heart failure · 2023Article
- Natural language processing for identification of hypertrophic cardiomyopathy patients from cardiac magnetic resonance reports.BMC medical informatics and decision making · 2022Article
- Multimodal deep learning enhances diagnostic precision in left ventricular hypertrophyEuropean heart journal. Digital health · 2022Article
- Successful pregnancy in left ventricular hypertrabeculation/noncompaction with implanted cardioverter/defibrillator and a variant in the TPM1 Gen (c.425A > T) in mother and child.Journal of cardiology cases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo validate diagnostic codes for hypertrophic cardiomyopathy (HCM), analyze misclassfications, and estimate the prevalence of HCM in an unselected Swedish regional cohort. PATIENTS AND
methodsUsing the hospitals' electronic medical records (used for the Swedish National Patient Register), we identified 136 patients from 2006 to 2016 with the HCM-related codes 142.1 and 142.2 (International Classification of Diseases).
resultsOf a total of 129 residents in the catchment area, 88 patients were correctly classified as HCM (positive predictive value 68.2%) and 41 patients (31.8%) were misclassified as HCM. Among the 88 HCM patients (52.2% males), 74 were alive and 14 were dead (15.9%). This yields an HCM prevalence of 74/183,337, that is, 4.0 diagnosed cases per 10,000 in the adult population aged ≥18 years. The underlying diagnoses of misclassified cases were mainly hypertension (31.7%) and aortic stenosis (22.0%). Other types of cardiomyopathies accounted for several cases of misclassification: dilated (nonischemic or ischemic), left ventricular noncompaction, and Takotsubo. Miscellaneous diagnoses were amyloidosis, pulmonary stenosis combined with ventricular septal defect, aortic insufficiency, athelete's heart, and atrioventricular conduction abnormality. The mean age was not significantly different between HCM and misclassified patients (65.8±15.8 vs 70.1±13.4 years;
conclusionOne-third of patients diagnosed as HCM are misclassified, so registry data should be interpreted with caution. A correct diagnosis is important for decision-making and implementation of optimal HCM care; efforts should be made to increase awareness of HCM and diagnostic competence throughout the health care system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.